Fetal Surgery for Myelomeningocele: Improved Outcomes & Standard of Care

The landscape of prenatal care for spina bifida, a birth defect that occurs when the spinal cord doesn’t close completely during pregnancy, is undergoing a subtle but significant shift. Recent research continues to reinforce the benefits of fetal surgery to repair open neural tube defects like myelomeningocele, potentially marking the first steps of a new era in fetal intervention. This approach, initially demonstrated in the landmark Management of Myelomeningocele Study (MOMS) over a decade ago, is increasingly becoming a standard option offered at specialized centers worldwide.

Understanding Myelomeningocele and Hydrocephalus

Myelomeningocele is the most severe form of spina bifida. It affects the spinal cord and the bones surrounding it. The condition can lead to a range of disabilities, including muscle weakness or paralysis, bowel and bladder control problems, and hydrocephalus – an abnormal buildup of fluid in the brain. Hydrocephalus, if left untreated, can cause increased pressure on the brain, leading to developmental delays and other complications. Traditionally, hydrocephalus associated with myelomeningocele has been managed with a shunt, a surgically implanted tube that drains excess fluid from the brain.

The MOMS trial, published in 2011, demonstrated that performing the myelomeningocele repair in utero – whereas the baby is still in the womb – could significantly reduce the severity of hydrocephalus and, lessen the demand for shunt placement after birth. The study also showed improvements in motor function, with a notable increase in the likelihood of independent walking by 30 months of age.

The MOMS Trial: A Closer Look

The Management of Myelomeningocele Study (MOMS) was a randomized controlled trial conducted across multiple centers in the United States. Researchers compared the outcomes of fetal surgery versus postnatal surgery for myelomeningocele. The trial involved 158 pregnant women carrying a fetus diagnosed with myelomeningocele. The primary endpoint was the proportion of infants requiring a shunt. The results showed a significantly lower rate of shunt placement in the fetal surgery group compared to the postnatal surgery group. While the MOMS trial was a pivotal moment, it’s important to remember that it wasn’t without limitations. The study focused on a specific population and the long-term effects continue to be evaluated.

Beyond Shunt Reduction: Broader Benefits

The benefits of fetal repair extend beyond simply reducing the need for shunts. The earlier intervention appears to lessen the neurological damage caused by the open defect, leading to improved motor skills and cognitive development. This is because the fetal brain is more adaptable and plastic than the postnatal brain, allowing it to better compensate for any remaining neurological deficits. However, it’s crucial to understand that fetal surgery isn’t a cure. Children who undergo fetal repair may still require ongoing medical care and support.

Who is Affected and Where is This Offered?

Spina bifida affects approximately 1,500 babies born in the United States each year, according to the Centers for Disease Control and Prevention. While the exact causes of spina bifida are not fully understood, certain factors, such as folic acid deficiency during pregnancy, can increase the risk. Fetal surgery for myelomeningocele is a complex procedure that requires a highly specialized team of surgeons, obstetricians, and other healthcare professionals. It is currently offered at a limited number of centers worldwide, typically those with extensive experience in fetal surgery and neurosurgical care.

Neurodevelopmental Outcomes and Long-Term Follow-Up

Recent research, including a study published in March 2023, continues to examine the long-term neurodevelopmental outcomes of children who underwent fetal repair for myelomeningocele. This study highlighted that even among children with myelomeningocele who did not require a shunt, ongoing monitoring and support are essential to optimize their neurodevelopmental potential. The Hydrocephalus Clinical Research Network is actively involved in ongoing studies to better understand the long-term effects of fetal repair and to identify strategies to improve outcomes.

Trial Endpoints and Uncertainty

It’s important to note that assessing the true benefits of fetal surgery is complex. While shunt reduction is a clear endpoint, evaluating improvements in motor function and cognitive development requires careful neurodevelopmental assessments over many years. There is also inherent variability in the severity of myelomeningocele, which can influence outcomes. Researchers are continually refining their assessment tools and statistical methods to account for these factors.

What Comes Next: Refining the Approach and Expanding Access

The field of fetal surgery for spina bifida is constantly evolving. Ongoing research is focused on identifying the optimal timing for surgery, refining surgical techniques, and developing new strategies to protect the fetal brain. There is also a growing effort to expand access to fetal surgery, making it available to more families who could benefit from this potentially life-changing intervention. Future trials may explore the use of biomarkers to predict which fetuses are most likely to benefit from surgery, and to personalize treatment plans. Continued long-term follow-up of children who have undergone fetal repair is crucial to fully understand the long-term benefits and risks of this approach.